ARTICLE | Clinical News
Tasquinimod: Phase III started
May 5, 2014 7:00 AM UTC
Active Biotech disclosed in its 1Q14 earnings that in February partner Ipsen began a double-blind, placebo-controlled, Asian Phase III trial to evaluate 0.25, 0.5 and 1 mg oral tasquinimod once daily ...